Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05264337
Other study ID # 2021-04840
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 14, 2022
Est. completion date January 2030

Study information

Verified date April 2023
Source Vastra Gotaland Region
Contact Henrik Kjölhede, MD, PhD
Phone +46-31-3421000
Email henrik.kjolhede@vgregion.se
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Lymphedema of the extremities is common after lymph node surgery in treating several forms of cancer, e.g., breast cancer. However, very little is known of the occurrence of lymphedema of the lower extremities after urologic surgery with lymph node dissection. This project aims to describe the frequency and grade of lymphedema arising after urologic surgery, using the Lymphedema Quality of Life Questionnaire (LymQOL), Delfin MoistureMeter D, and lower limb volume measurements.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date January 2030
Est. primary completion date January 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients undergoing urologic surgery with lymph node dissection Exclusion Criteria: - None

Study Design


Intervention

Other:
Self-reported lymphedema
Lymphedema as reported by LymQOL questionnaire.
Dielectric constant ratio
Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.
Limb volume
Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.

Locations

Country Name City State
Sweden Sahlgrenska University Hospital Göteborg
Sweden Örebro University Hospital Örebro

Sponsors (1)

Lead Sponsor Collaborator
Vastra Gotaland Region

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with self-reported lymphedema at 12 months Frequency and grade of self-reported swelling of the lower extremities as graded by LymQOL questionnaire 12 months after surgery
Primary Number of patients with self-reported lymphedema at 24 months Frequency and grade of self-reported swelling of the lower extremities as graded by LymQOL questionnaire 24 months after surgery
Primary Change in tissue water content measured by MoistureMeterD Compact at 12 months Percent tissue water content calculated from the dielectric constant as measured by MoistureMeterD Compact 12 months after surgery
Primary Change in tissue water content measured by MoistureMeterD Compact at 24 months Percent tissue water content calculated from the dielectric constant as measured by MoistureMeterD Compact 24 months after surgery
Primary Change in lower limb volume calculated by measuring the circumference of the lower extremities at 12 months 12 months after surgery
Primary Change in lower limb volume calculated by measuring the circumference of the lower extremities at 24 months 24 months after surgery
Secondary Number of patients with self-reported lymphedema at 1 month Frequency and grade of self-reported swelling of the lower extremities as graded by LymQOL questionnaire 1 month after surgery
Secondary Number of patients with self-reported lymphedema at 3 months Frequency and grade of self-reported swelling of the lower extremities as graded by LymQOL questionnaire 3 months after surgery
Secondary Number of patients with self-reported lymphedema at 6 months Frequency and grade of self-reported swelling of the lower extremities as graded by LymQOL questionnaire 6 months after surgery
Secondary Change in tissue water content measured by MoistureMeterD Compact at 1 month Percent tissue water content calculated from the dielectric constant as measured by MoistureMeterD Compact 1 month after surgery
Secondary Change in tissue water content measured by MoistureMeterD Compact at 3 months Percent tissue water content calculated from the dielectric constant as measured by MoistureMeterD Compact 3 months after surgery
Secondary Change in tissue water content measured by MoistureMeterD Compact at 6 months Percent tissue water content calculated from the dielectric constant as measured by MoistureMeterD Compact 6 months after surgery
Secondary Change in lower limb volume calculated by measuring the circumference of the lower extremities at 1 month Measurements of circumference every 6 cm along the lower limbs. 1 month after surgery
Secondary Change in lower limb volume calculated by measuring the circumference of the lower extremities at 3 month Measurements of circumference every 6 cm along the lower limbs. 3 month after surgery
Secondary Change in lower limb volume calculated by measuring the circumference of the lower extremities at 6 month Measurements of circumference every 6 cm along the lower limbs. 6 month after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04964271 - Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
Completed NCT02546908 - A Registry of Participants With Prostate Cancer in Asia
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT01683994 - Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT04838613 - Study of Diagnostic Performance of [18F]CTT1057 in BCR Phase 3
Completed NCT02364531 - A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Completed NCT01929655 - Japanese BAY88-8223 Monotherapy Phase II Study Phase 2
Active, not recruiting NCT05022849 - A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants Phase 1
Completed NCT03261999 - Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer Phase 3
Terminated NCT04907227 - Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension Phase 3
Active, not recruiting NCT03587285 - A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT02217566 - Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy Phase 2
Not yet recruiting NCT04101305 - Measurement of Circulating Tumor Cells in Prostate Cancer
Recruiting NCT03066154 - Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer Phase 1
Active, not recruiting NCT02950064 - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Phase 1
Withdrawn NCT02905201 - A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) N/A
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Terminated NCT01420965 - Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer Phase 2
Completed NCT01441713 - Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer N/A